- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Uncontrolled severe asthma Uncontrolled severe allergic asthma Severe chronic spontaneous urticaria
- Meeting Date: March 2025
- Public Summary Document (PSD) March 2025 PBAC Meeting - (PDF)
- Public Summary Document (PSD) March 2025 PBAC Meeting - (Word)
Omalizumab – March 2025
Omalizumab; Injection 75 mg in 0.5 mL single dose pre-filled syringe, Injection 150 mg in 1 mL single dose pre-filled syringe; Omlyclo®
Last updated
12 March 2025